LIPUM Stock Overview
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lipum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.70 |
| 52 Week High | kr15.00 |
| 52 Week Low | kr5.78 |
| Beta | 0.11 |
| 1 Month Change | 1.52% |
| 3 Month Change | 7.72% |
| 1 Year Change | -39.09% |
| 3 Year Change | -73.20% |
| 5 Year Change | n/a |
| Change since IPO | -70.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIPUM | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -4.3% | -1.2% | -0.7% |
| 1Y | -39.1% | -5.1% | 8.7% |
Return vs Industry: LIPUM underperformed the Swedish Biotechs industry which returned -5.1% over the past year.
Return vs Market: LIPUM underperformed the Swedish Market which returned 8.7% over the past year.
Price Volatility
| LIPUM volatility | |
|---|---|
| LIPUM Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: LIPUM's share price has been volatile over the past 3 months.
Volatility Over Time: LIPUM's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Ola Sandborgh | www.lipum.se |
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.
Lipum AB (publ) Fundamentals Summary
| LIPUM fundamental statistics | |
|---|---|
| Market cap | kr62.41m |
| Earnings (TTM) | -kr37.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs LIPUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPUM income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr37.18m |
| Earnings | -kr37.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 38.5% |
How did LIPUM perform over the long term?
See historical performance and comparison